UDCA in primary sclerosing cholangitis
Does UDCA improve outcomes in PSC
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
ursodeoxycholic acid improves biochemical liver function tests in PSC but has not been shown to improve symptoms, liver histology, or time to treatment failure/transplant-free survival in controlled trials 1. it also does not reduce the risk of colorectal adenomas or colon cancer in patients with ulcerative colitis and PSC 2,3, and adding mycophenolate mofetil provides no additional benefit over UDCA alone 4. 1–4
What is known:
- In controlled trials UDCA does not improve symptoms or liver-biopsy histology and does not prolong time to treatment failure or survival without transplantation. 1
- A meta-analysis of four studies (n=281) found no significant reduction in adenoma or colon cancer risk with UDCA in UC-PSC patients. 3
- High-dose UDCA does not prevent colorectal neoplasia, and its use for colorectal cancer chemoprevention in PSC-IBD has been questioned. 2
- Adding mycophenolate mofetil to UDCA provides no additional benefit over standard UDCA alone. 4
What is unknown / caveats:
- Controlled trials and a colon-cancer meta-analysis show no benefit for hard outcomes 1,3, and high-dose UDCA specifically was stopped for futility and harm (see the required-context box below)
- Much of the retrieval is reference lists and secondary reviews rather than primary outcome data
- The excerpts note UDCA improves biochemistry and is described as low-risk, but this is a surrogate marker, not a clinical outcome 1
- The excerpts do not resolve whether any UDCA dose or subgroup meaningfully affects long-term liver outcomes.
References
- Lamers CB. Treatment of extraintestinal complications of ulcerative colitis. Eur J Gastroenterol Hepatol. 1997;9:850-3. PMID: 9355781.
- Lindström L, Boberg KM, Wikman O, Friis-Liby I, Hultcrantz R, Prytz H, Sandberg-Gertzén H, Sangfelt P, Rydning A, Folvik G, Gangsøy-Kristiansen M, Danielsson A, Bergquist A. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia. Aliment Pharmacol Ther. 2012. PMID: 22221173.
- Ashraf I, Choudhary A, Arif M, Matteson ML, Hammad HT, Puli SR, Bechtold ML. Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis. Indian J Gastroenterol. 2012. PMID: 22528343.
- Sterling RK, Salvatori JJ, Luketic VA, Sanyal AJ, Fulcher AS, Stravitz RT, Contos MJ, Mills AS, Shiffman ML. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther. 2004. PMID: 15521841.
- Habeeb TAAM, Hussain A, Podda M, Cianci P, Ramshaw B, Safwat K, Amr WM, Wasefy T, Fiad AA, Mansour MI, Moursi AM, Osman G, Qasem A, Fawzy M, Alsaad MIA, Kalmoush AE, Nassar MS, Mustafa FM, Badawy MHM, Hamdy A, Elbelkasi H, Mousa B, Metwalli AM, Mawla WA, Elaidy MM, Baghdadi MA, Raafat A. Hepatobiliary manifestations following two-stages elective laparoscopic restorative proctocolectomy for patients with ulcerative colitis: A prospective observational study. World J Gastrointest Surg. 2023;15:234-248. PMID: 36896298.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
⚠ Required context not in this corpus (severe). The high-dose UDCA (28-30 mg/kg/d) trial in PSC was TERMINATED at 6 years for futility, and reported HARM: a 2.3x higher risk of the primary endpoint, 2.1x higher death/transplantation/minimal listing criteria (P = 0.04), and serious adverse events in 63% vs 37% (Lindor 2009, PMID 19585548; Imam 2011, PMID 21957881).
Why this matters: An answer that calls high-dose UDCA merely 'unproven', or leaves open that a higher dose might help, can push a clinician toward a dose an RCT stopped for harm.
Added by the landmark interlock. This corpus is surgical in scope and cannot admit the source paper (PMID 19585548, 21957881). Not generated by the RAG.
Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.
Reviewer notes